Activity Overview
This online, on-demand virtual symposium brings together renowned experts in psychiatry. In this educational program, these experts discuss long-acting injectables for the treatment of patients with schizophrenia as well as best practices for motivational interviewing. This program includes an interview with a patient who has spent the past 30 years dealing with schizophrenia.
This educational activity is an archive of the live virtual symposium held on July 10, 2026.
Target Audience
Target Audience: This educational activity is directed toward psychiatrists, psychiatric nurse practitioners, physician assistants, registered nurses, pharmacists, and other health care providers involved in the management of patients with schizophrenia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze clinical trial data for long-acting injectable agents for schizophrenia
- Integrate counseling strategies for long-acting injectable medications into individualized management plans for patients with schizophrenia
Gerald Maguire, MD
Director of Residency Training in Psychiatry
College Medical Center
UC Riverside Health–Riverside Downtown
Riverside, CA
Disclosures: Speakers Bureau: Alkermes, Axsome Therapeutics, Bristol Myers Squibb, Johnson & Johnson, Neurocrine, Otsuka, Vanda; Grant/Research Funding (to institution): AbbVie, Bristol Myers Squibb, Compass, Cybin, Emalex Biosciences, Johnson & Johnson, LB Pharmaceuticals, MapLight, Minerva, Noema, Vistagen, Xenon; Ownership Interests in Privately Held Companies: StutterSenseAI
Jacob Hanaie, PharmD, APh, BCPP
Director of Pharmacy
Kedren Acute Psychiatric Hospital and Community Mental Health
Center
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Alkermes, Bristol Myers Squibb, Teva; Speakers Bureau: AbbVie, Alkermes, Bristol Myers Squibb, Luye, Teva, Vertex
Charles Nguyen, MD, DFAPA
UC Riverside School of Medicine
Riverside, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Johnson
& Johnson, Neurocrine, Otsuka; Speakers Bureau: Axsome
Therapeutics, Bristol Myers Squibb, Johnson & Johnson, Neurocrine, Otsuka,
Teva, Tonix
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
